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Abstract 20 
UV-curable gels, used as nail cosmetics for their in vivo durability, were reported to be 21 
promising as topical nail medicines. Our first aim was thus to investigate whether such 22 
durability applies to drug-loaded formulations. This was found to be true.  However, ethanol 23 
inclusion in the pharmaceutical formulation (to enable drug loading) reduced the in vivo 24 
residence.  The second aim was therefore to determine any other effects of ethanol, and if 25 
ethanol could be avoided by the choice of monomers.  Thus, three methacrylate monomers, 26 
ethyl methacrylate, isobornyl methacrylate and 2 -hydroxyethyl methacrylate (HEMA) were 27 
selected, and their influence on the formulation properties were determined.  Ethanol and 28 
the methacrylate monomer influenced some (but not all) of the formulation properties.  The 29 
most significant was that HEMA could dissolve drug and enable the preparation of ethanol-30 
free, drug-loaded formulations, which would benefit in vivo residence.  The absence of 31 
ethanol reduced drug loading, release and ungual flux, but had no negative impact on the in 32 
vitro anti-fungal efficacy.  Thus, judicious selection of gel components enabled the exclusion 33 
of ethanol.  The long in vivo residence, little residual monomers, sufficient ungual 34 
permeation and in vitro anti-fungal activity of the gels indicate their potential as anti-35 
onychomycotic topical medicines. 36 
37 
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1. Introduction 38 
Onychomycosis which is defined as fungal infection of the nail plate and/or nail bed, is a 39 
significant medical burden, affecting 10% of the general population, 20% of those over 60 40 
years old, up to 50% of those over 70 years old and up to one-third of diabetics (Thomas et 41 
al., 2010) .  The disease is often of long duration, is ‘more than a cosmetic problem’ (Scher, 42 
1994), significantly affects patients’ quality of life (Lubeck et al., 1993)  and is recalcitrant to 43 
treatment (Arrese and Pierard, 2003; Daniel and Jellinek, 2010).  Oral therapy with anti-44 
fungal agents, such as terbinafine and itraconazole, is the treatment mainstay.  However, 45 
drug efficacy is far from ideal, with pooled mycological cure rates in randomised controlled 46 
trials being 76 ±3% for terbinafine and 63% ±7%  for itraconazole (Gupta et al., 2004) .   The 47 
disadvantages of oral therapy, such as the potential for adverse systemic effects and drug 48 
interactions means that topical therapy is highly attractive, and a number of topical 49 
formulations have been tested, patented and a few have been marketed, compiled in, for 50 
example (Saner et al., 2014; Shivakumar et al., 2012)  .  Unfortunately, the success rates of 51 
topical therapy are even lower, as indicated in the medicines’ patient information leaflets, 52 
and compiled in (Murdan, 2016) .  A number of possible reasons for the low clinical cure of 53 
therapy have been proposed, such as inaccurate diagnosis, incorrect antifungal or delivery 54 
modality, presence of dormant fungal conidia (which can germinate and give rise to further 55 
infection), resistant fungal species, dermatophytoma (areas of the nail filled with debris of 56 
keratin and a large amount of fungi material which is more impermeable to drug),  low 57 
patient compliance,  and insufficient drug permeation into and through the nail plate for 58 
anti-fungal kill (Baran et al., 2005; Goodfield and Evans, 2000).   59 
 60 
Insufficient drug in the nail could be due to the fact that the commercially available topical 61 
formulations do not have a continuous residence on the nail plate following application, and 62 
thus do not maximise the duration of ungual drug permeation.  For example, the most 63 
recently marketed formulations Jublia®, Kerydin® and Onytec® are easily washed off, and 64 
the patient information leaflets recommend application prior to bedtime to enable ungual 65 
drug permeation to occur for at least the duration of sleep (AnacorPharmaceuticals, 2014; 66 
KakenPharmaceutical, 2014; Onytec).  Loceryl® is meant for weekly application (Galderma, 67 
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2015). However, in vivo experiments have shown that the Loceryl film does not stay intact 68 
on the nail for the duration of a whole week, at least on fingernails (Murdan et al., 2015).  69 
Non-continuous residence of drug formulations on the nail could be compounded by poor 70 
patient compliance.  While the latter is not known, the extensive literature on (fairly low) 71 
patient compliance in general, suggests that compliance to topical nail medicines is likely to 72 
be lower than required. 73 
 74 
Patient compliance could be improved by longer-lasting topical formulations and we have 75 
previously proposed UV-curable gels as topical formulations which are likely to have long in 76 
vivo residence on the nail (Kerai et al., 2015). In the work discussed in this paper, the first 77 
aim was thus to investigate the in vivo residence of these formulations.  During this study, it 78 
was found that, while the UV-cured films have a fairly long in vivo residence, inclusion of 79 
ethanol in the formulation (which enabled sufficient drug loading) reduced the in vivo 80 
residence.  The second aim was therefore to determine what other effects ethanol had, if 81 
these effects were independent of the other gel components, and whether the inclusion of 82 
ethanol could be avoided. 83 
 84 
Cosmetic UV curable gel formulations typically consist of three components: i) a urethane 85 
methacrylate, ii) a (meth)acrylate based monomer and iii) a polymerisation photoinitiator.  86 
The pharmaceutical UV curable gel formulation reported previously  consisted of these, 87 
specifically, diurethane dimethacrylate (DUDMA), ethyl methacrylate (as the (meth)acrylate 88 
based monomer) and 2-hydroxy-2-methylpropiophenone as the photoinitiator, as well as a 89 
drug (amorolfine HCl or terbinafine HCl) and a solvent (ethanol).  In order identify more 90 
appropriate gel components (to avoid the use of ethanol), one could screen alternative 91 
urethane-based methacrylates such as Di-HEMA trimethylhexyl dicarbomate, 92 
photoinitiators such as 1-hydroxycyclohexyl phenyl ketone and different (meth)acrylate 93 
based monomers.  In this work, we decided to keep DUDMA as the backbone of the 94 
formulation as it produces a strong film with exceptional abrasion resistance and durability, 95 
and 2-hydroxy-2-methylpropiophenone as the photoinitiator, and to screen different 96 
methacrylate based monomers.  Thus, 2-hydroxyethyl methacrylate (HEMA) and isobornyl 97 
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methacrylate (IBOMA), in addition to ethyl methacrylate (EMA) were selected as the 98 
methacrylate based monomers.   The influence of these monomers and of ethanol on the 99 
gel and film properties were determined, and correlations among the different properties of 100 
the films formed by photo-polymerisation were explored.   101 
 102 
2. Materials and Methods 103 
2.1  Materials 104 
Amorolfine HCl was purchased from Ranbaxy Research Laboratories (Haryana, India) and 105 
terbinafine HCl from AK Scientific (CA, USA). Diurethane dimethacrylate, ethyl methacrylate, 106 
isobornyl methacrylate, 2-hydroxyethyl methacrylate, 2-hydroxy-2-methylpropiophenone, 107 
absolute ethanol, methanol, propan-2-ol, sodium chloride, triethylamine, phosphoric acid 108 
85% wt solution in water and trifluoroacetic acid and a dialysis tubing cellulose membrane 109 
(MW 10281) were purchased from Sigma–Aldrich (Dorset, UK). Acetonitrile HPLC gradient 110 
grade was purchased from Fisher Scientific (Hertfordshire, UK). A 36 Watt Cuccio 111 
Professional UVA nail lamp was purchased from Amazon UK.  Nail & Beauty Emporium lint-112 
free wipes (4 ply) were purchased from Just Beauty UK, an online retailer specialising in 113 
professional beauty, hair and skin products.  Sabouraud dextrose agar was purchased from 114 
Oxoid Ltd (Basingstoke, UK).  One dermatophyte strain, Trichophyton rubrum (CBS 118892), 115 
was used. Curanail® nail lacquer was used as a control in some experiments and was 116 
purchased from pharmacies in the UK.  Human nail clippings (fingernails) were obtained 117 
from healthy volunteers aged between 18 and 65 years (following ethics approval). 118 
 119 
2.2 Determination of drug (amorolfine HCl and terbinafine HCl) solubility in methacrylate 120 
monomers  121 
The saturation solubility of the two drugs in EMA, HEMA and IBOMA was determined as 122 
described in (Kerai et al., 2015) . 123 
 124 
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2.3 Preparation of UV gels and films  125 
Drug-free gel formulations were prepared by mixing DUDMA with a methacrylate monomer 126 
(EMA or IBOMA or HEMA) at 85:15 or 75:25 (for HEMA only) v/v ratios, the photoinitiator at 127 
3% v/v of the methacrylate mixture, with or without ethanol at 25% v/v of the methacrylate 128 
mixture, and leaving the mixture to stir overnight, which produced a clear homogenous 129 
solution. Drug-loaded formulations were prepared by first dissolving the drug in ethanol, 130 
and then adding the methacrylates and photoinitiator and leaving the mixture to stir 131 
overnight, which also produced a clear homogenous solution. To prepare the films, the gel 132 
mixture was applied on a microscope glass slide using a pipette tip (30 µl to an area of 15 133 
mm x 15 mm as a single layer), which was then placed under the UVA lamp for two minutes.  134 
This caused curing of the formulation and formation of a film. The surface of the film was 135 
wiped with propan-2-ol using a super absorbent 4 ply lint-free nail wipe to remove the 136 
oxygen inhibition layer (an unreacted monomer layer). This revealed a glossy polymer film, 137 
which was then removed from the glass slide using a scalpel and characterised. 138 
 139 
A curing time of 2 minutes was selected after experimenting with 0.5-5 minutes of UVA 140 
exposure, and measuring the gel blend to polymer film mass yield, the alkene-to-alkane 141 
degree of conversion (the route of polymerisation), and the levels of residual monomers in 142 
the polymer film.  The measurements (Supplementary Data 1a) showed that a cure time of 143 
two minutes was sufficient for maximal mass yield and degree of conversion and for 144 
minimal residual monomers. 145 
 146 
2.4 In vitro characterisation of the gels and UV-cured films  147 
The in vitro properties of the gels and of the films, such as gel viscosity, maximum drug 148 
loading, gel-to-film mass yield, degree of conversion and the films’ appearance, 149 
microstructure, crystallinity, level of residual monomers, drug-polymer interactions, glass 150 
transition temperature, adhesion, water sensitivity, drug release and ungual permeation 151 
were determined as described in (Kerai et al., 2015) . The films’ mass change with time was 152 
monitored over 28 days under the following testing conditions: 30°C ± 2°C and 50% RH ± 5% 153 
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RH, by placing  the films in a desiccator containing a saturated solution of magnesium 154 
nitrate and placing this in a 30⁰C oven. The film’s mass was recorded on days 0, 1, 2, 3, 7, 14, 155 
21 and 28.   The film thickness was measured using a Sealey AK9635D 0–25 mm Digital 156 
External Micrometer (PVR Direct, Bristol, UK). Each film was measured at three separate 157 
points and an average was taken, and each test was carried out in triplicate. Precautions 158 
were taken to measure the thickness without compressing the polymer film. The uniformity 159 
of thickness within each film and between films was calculated using the following formula: 160 
                
                  
    
      
 161 
2.5 In vivo fingernail residence of UV-cured polymer films 162 
Following approval by the UCL School of Pharmacy's ethics committee (Project 5337/002), 163 
12 volunteers (aged between 18 – 65 years) with healthy fingernails were recruited. For 164 
each volunteer, a single layer of the UV-curable gel formulation was applied on the five 165 
fingernail plates of one hand using a pipette tip, leaving a formulation-free margin 166 
(approximately 1-2 mm) near the nail plate perimeter, ensuring that skin contact was 167 
avoided. This hand was then placed under a UVA nail lamp for two minutes. Subsequently, 168 
the surface of the cured gel on each nail plate was wiped with propan-2-ol using a super 169 
absorbent nail wipe to remove the oxygen inhibition layer, leaving behind a thin, smooth, 170 
transparent film. The procedure was repeated on the other hand. The nails were visually 171 
observed daily to estimate the percentage of UV-cured film remaining on the fingernails. 172 
Estimation was facilitated by visually dividing the nail plate into quadrants which were then 173 
further divided into sub-quadrants. Daily observation was continued until the UV-cured 174 
films had completely dislodged from the nail plate or for up to 28 days, whichever was 175 
sooner. After 28 days, the remaining film was removed using a wooden stick 10 minutes 176 
following the application of a cotton pad soaked with acetone over the film. The experiment 177 
was then repeated with a different formulation. A total of four UV-curable gel formulations 178 
(which contained the monomer EMA, ± solvent and drug) were tested, and each 179 
formulation was tested on a minimum of six volunteers.  180 
 181 
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2.6 In vivo occlusivity of UV-cured polymer films 182 
The occlusivity of UV-cured films was assessed by measuring trans-onycheal water loss 183 
(TOWL) from the healthy fingernail plates of volunteers before and after the application of 184 
the gel formulations (which were applied as described in Section 2.5). Curanail® lacquer film 185 
was used as control, and was applied as instructed in the packaging (i.e. after filing and 186 
cleansing). Prior to TOWL measurements, the volunteers had rested for at least 60 minutes 187 
in the laboratory, and avoided contact with water. TOWL measurements were obtained 188 
using a Biox Aquaflux Model AF200 equipped with an in vivo nail cap (Biox Systems Ltd, 189 
London, UK). The finger was placed on a flat surface for support and the Aquaflux 190 
measurement head was placed on the centre of the nail plate. No pressure was applied as 191 
the weight of the measurement head itself ensured a good seal, and measurements were 192 
collected using AquaFlux version 4.8. Water vapour flux density versus time curves were 193 
recorded until a steady-state TOWL reading was obtained (between 90 - 120 seconds, with a 194 
mean of 10 points), and five repeats were obtained per formulation. All measurements were 195 
conducted in the same laboratory, where the ambient temperature and air humidity 196 
fluctuated between 22 - 26⁰C and 38 - 48% respectively. The % reduction in TOWL  was 197 
calculated as follows: 198 
                    
                                                                          
                                      
     
 199 
A greater reduction in TOWL indicates higher occlusivity of the film.  200 
 201 
2.7  In vitro antifungal efficacy of UV gels against T. rubrum 202 
The dermatophyte T. rubrum was chosen as it is the most common causative organism of 203 
onychomycosis.  The ability of the formulations to inhibit fungal growth was used as a 204 
measure to compare formulations.  The classical disc diffusion method was adapted, where 205 
the ‘disc’ was replaced by a circular piece of nail clipping onto which a gel formulation had 206 
been cured, taking care to leave a formulation-free margin at the nail edge, such that the 207 
drug would have to be permeate into and through the nailplate to reach the agar gel.  This 208 
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method was used as there is currently no standard in vitro method to assess the anti-fungal 209 
efficacy of anti-onychomycotic formulations.  210 
 211 
Preparation of SDA plates: A Sabouraud Dextrose Agar (SDA) solution (65 g SDA/L of distilled 212 
water) was prepared, sterilised (by autoclaving at 1210C for 15 minutes) and poured into 213 
90mm petri dishes (25 ml of agar solution/dish) and allowed to solidify overnight.  214 
Preparation of test plates: A cork borer (8mm-internal diameter, sterilised by dipping in 215 
ethanol then flamed) was punched into the centre of a SDA plate (prepared above) to 216 
remove a plug of agar, which was discarded. The cork borer was sterilised once more, and 217 
used to punch out a T. rubrum plug from a fresh culture plate of T. rubrum. The fungal plug 218 
was inserted into the slot created in the first SDA plate, and the latter was then incubated at 219 
32⁰C for three days to ensure that the fungal culture grew sufficiently and to identify (and 220 
remove) defective plates, if any. During this time, the T. rubrum culture grew to 10 mm in 221 
diameter. 222 
Preparation of nail clippings with drug formulations: Human fingernail clippings were 223 
washed with water, cut to size (circular, with a diameter of 3 mm) and autoclaved at 1200C 224 
for 20 minutes in order to sterilise them (autoclaving did not affect the nail properties -225 
indicated by the lack of change in solvent uptake). Two µl of a formulation was applied on 226 
the nail surface, ensuring a small formulation-free perimeter at the edge of the nail surface.  227 
For the control Curanail, the lacquer was allowed to air-dry.  For the UV gels, the nail was 228 
placed under an UVA lamp for 2 minutes, after which the surface of the film produced was 229 
wiped with propan-2-ol using a nail wipe.  230 
Details of the formulations tested are shown in Table 1.  Drug-free counterparts of these 231 
formulations were also tested to assess the influence, in any, of the UV-cured film itself 232 
against T. rubrum. In addition, Curanail® nail lacquer (containing 5% w/v amorolfine HCl) 233 
was tested as a positive control. 234 
Evaluation of anti-fungal efficacy:  Three days following the insertion of the fungal plug into 235 
a prepared SDA plate, the latter was marked into four quadrants (which enabled the testing 236 
of one test formulation on three nail clippings, and one drug-free formulation on a fourth 237 
nail clipping per plate).  Using a sterile tweezer, the prepared nail clippings were carefully 238 
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placed on the agar gel surface at a distance of 20 – 25 mm from the centre of the plate.  This 239 
distance was chosen to allow sufficient time for the drug to penetrate into and through the 240 
nail into the agar gel, based on the ungual drug permeation results and T. rubrum growth 241 
rates from preliminary studies. Thus, each plate contained a triplicate set of the same 242 
formulation in addition to a drug-free control. 243 
In addition to the test plates, two controls were set up: i) a formulation-free, nail-free 244 
negative control was set up to monitor the growth of T. rubrum, and ii) a control plate 245 
containing 3 equally-spaced nail clippings with drug-free UV-cured films on their surface, 246 
with the clippings being placed at a distance of 20 – 25 mm from the centre of the plate.   247 
The SDA plates were incubated at 32⁰C for as long as it took the T. rubrum culture to grow 248 
over the entire SDA plate’s surface (or when no further growth was detected). During this 249 
period, the plates were observed daily to monitor the growth of T. rubrum and to monitor 250 
the formation of a zone of inhibition, if any, around the nail clippings.  251 
 252 
2.8 Statistical analysis 253 
All the experiments described above were repeated three times (except for the in vitro drug 254 
permeation study which was repeated six times, in vivo residence studies where n=60 (10 255 
fingernails x 6 volunteers) and in vivo TOWL measurements where n=5). Statistical 256 
calculations were conducted using SPSS 22.  Repeated measures ANOVA and post hoc Tukey 257 
tests were performed on the drug release, ungual permeation and in vivo residence profiles 258 
over time.  When n ≥5, Students t-tests were performed to compare two data sets while 259 
ANOVA, with post hoc Tukey were conducted to compare more than two data sets.   Non-260 
parametric tests were used when n=3; specifically, Mann-Whitney to compare two groups, 261 
and Kruskal-Wallis, followed by Nemenyi’s tests to compare more than two groups.   262 
 263 
3. Results and Discussion 264 
3.1  In vivo residence of UV-cured films 265 
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The in vivo residence of UV-cured films, and of Curanail nail lacquer (used as a commercially 266 
available control) is shown in Figure 1. It can be seen that the UV-cured films have a much 267 
longer residence on the nail compared to Curanail (p<0.05).   Four weeks after gel 268 
application and film formation, a considerable proportion of the film remained on the nails.  269 
This shows that the UV-cured films have promise as long-term topical nail medicines, 270 
continuously allowing drug to permeate into the nail, and thereby improve the success of 271 
topical nail medicines. A longer residence on the nail could also improve patient compliance 272 
as less frequent drug application will be needed.   273 
 274 
The longer residence of the ethanol-free UV-cured formulation compared to ethanol-275 
containing ones (p<0.05) indicates that ethanol-free pharmaceutical formulations would be 276 
advantageous for nail medicines.  The presence of ethanol had enabled drug loading in the 277 
formulations and had influenced some, but not all of the formulation properties 278 
investigated (Kerai et al., 2015) .  In order to further explore the influence of ethanol on the 279 
formulation properties and determine whether such influence was independent of the 280 
nature of the other gel components, and evaluate the possibility of developing ethanol-free 281 
formulations, two additional methacrylate-based monomers (in addition to ethyl 282 
methacrylate) were selected and their formulations were characterised as discussed below.  283 
 284 
3.2  Selection of the nature and proportion of the methacrylate monomers in the gel  285 
In contrast to cosmetic UV gels examined, which contain a mixture of acrylate- and 286 
methacrylate-based monomers, only methacrylate-based monomers were included in our 287 
pharmaceutical formulations due to their lower toxicity and lower sensitising capacity 288 
(Clemmensen, 1984; Rietschel et al., 2008; Yoshii, 1997), which render them more 289 
favourable for nail products (Schoon, 2010).  Of the possible methacrylate-based monomers, 290 
ethyl methacrylate (EMA), hydroxyethyl methacrylate (HEMA) and isobornyl methacrylate 291 
(IBOMA) were selected due to their unique structures (Figure 2), which could differently 292 
impact the resulting films’ properties, and which would, in turn, enable the exploration of 293 
correlations among the formulation properties.  EMA was expected to enhance film 294 
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flexibility, IBOMA – with its cyclic group - could affect the resulting film’s mechanical 295 
strength and glass transition temperature while HEMA – with its hydroxyl group – could 296 
affect the hydrophilic/hydrophobic character of the resulting film.  The three monomers 297 
also have different solvencies for the two drugs being tested (Table 2), and the higher 298 
solvency of HEMA towards the drugs enables the development of ethanol-free gels. 299 
 300 
The ratio of diurethane dimethacrylate (DUDMA) to methacrylate monomer (EMA or HEMA 301 
or IBOMA) in the gel formulations were generally kept at 85:15 % v/v as in (Kerai et al., 302 
2015) , except for the ethanol-free HEMA-based formulations.  As HEMA could dissolve the 303 
drugs to some extent (Table 2), it was possible to produce drug-loaded gels without ethanol.  304 
In this case, the proportion of HEMA was increased to enable sufficient drug loading.  Thus 305 
HEMA-containing formulations were also produced at a DUDMA:HEMA ratio of 75:25 %v/v. 306 
 307 
The photoinitiator (2-hydroxy-2-methylpropiophenone) was kept at 3% v/v of the 308 
methacrylate mixture as this was found to be sufficient for maximal gel-to-polymer degree 309 
of conversion and mass yield and minimal levels of residual monomers (supplementary data 310 
1b).  Ethanol was included at a concentration of 25% v/v as this concentration increased the 311 
formulations’ drug loading and did not compromise the films’ water-resistance (Kerai et al., 312 
2015). Ethanol-free formulations of HEMA were also produced. 313 
 314 
3.3 Influence of gel components on its properties 315 
 316 
3.3.1   Gel viscosity: The viscosities of the gels (± ethanol and ± drug) are shown in the 317 
Supplementary Data 2.  In ethanol-free gels, the nature and proportion of the methacrylate 318 
monomer had a direct influence on viscosity (p<0.05), which was between 162 mPas and 319 
672 mPas.  Inclusion of ethanol (whose viscosity is 1 mPas) considerably reduced the gel and 320 
all ethanol-containing gels (with/without drug) had similar viscosities of 15-25 mPas 321 
(p>0.05).  Inclusion of the very low viscosity ethanol overrides any influence of the 322 
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methacrylate monomer on gel viscosity. Gel viscosity is an important parameter: too high 323 
viscosity will cause difficulty during gel application, while insufficient viscosity will result in 324 
the gel spreading from the nail plate into the nail folds.  Excessive gel spreading is 325 
undesirable to avoid contact between the gel (containing potentially allergenic and 326 
sensitising monomers) and the skin.  The viscosities of these gels are deemed to be 327 
appropriate as the gel could be applied to the nail in volunteers, without any problems 328 
(Section 2.5). 329 
 330 
3.3.2  Drug loading and stability in gels:  Drug loading in a gel (Table 3) depended on the 331 
drug’s solubility in ethanol and in the methacrylate-based monomer, the drugs being 332 
insoluble in DUDMA (Kerai et al., 2015). Thus, gels containing HEMA and ethanol dissolved 333 
the most drug due to the greater drug solvency of HEMA.  Terbinafine loading was higher 334 
than that of amorolfine, due to its greater solubility in ethanol (Kerai et al., 2015) .  Over a 335 
period of six months, all the drug-loaded gels (stored under accelerated stability conditions) 336 
showed no change in colour, no visible signs of drug precipitation, and no change in drug 337 
concentration. The UV-curable gel formulations were therefore considered stable and 338 
suitable for further development.   339 
 340 
3.3.3  Polymerisation, degree of conversion and levels of residual monomers: Exposure of 341 
the gels to UVA initiates polymerisation between DUDMA and the methacrylate-based 342 
monomer (EMA or IBOMA or HEMA), where the original alkene bonds in the acrylate 343 
moieties are converted to alkane ones.  The degree of alkene-to-alkane conversion (DC) was 344 
between 56% and 68% (Supplementary data 3a).  Ethanol inclusion in the gels led to 345 
significantly higher (p<0.05) degrees of conversion, possibly due to the lower gel viscosities, 346 
which could have enabled increased reaction among the more mobile reactants.  In contrast, 347 
the nature of the methacrylate-based monomer (EMA, IBOMA, HEMA) and the presence of 348 
drug did not influence DC (p>0.05). 349 
 350 
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Very low levels of residual monomers (≤1% DUDMA, ≤ 0.005% EMA, ≤0.004% IBOMA and 351 
≤0.005% HEMA) were found in drug-containing films (Supplementary data 3b), which 352 
indicates that the much less than 100%  alkene-to-alkane degrees of conversion seen are 353 
due to the presence of unreacted alkene groups within the polymer, rather than unreacted 354 
monomers. It appears that most of the methacrylate monomers in the UV gel are involved 355 
in the polymerisation process, while a large number of the alkene groups are not.  The very 356 
low levels of residual monomers make the films attractive drug carriers, as the potential for 357 
allergic reactions (which is linked to monomers) is reduced. 358 
 359 
 360 
3.4 Influence of gel components on the properties of the UV-cured films 361 
 362 
3.4.1 Film macro-and micro- structure, amorphicity, FTIR: All the UV-cured films 363 
(irrespective of monomer nature, and presence or absence of ethanol and of drug) were 364 
visually smooth, transparent, had uniform thickness (≥95%), were amorphous, and were 365 
aesthetically acceptable as topical drug carriers. Scanning electron microscopy revealed a 366 
generally rough film surface on the side that was exposed to UV light, a much smoother 367 
surface where the film had been formed in contact with the support and a fairly dense film 368 
cross-section (Figure 3).  Film thickness was about 200 µm, with no influence of drug or of 369 
nature of the monomer (p>0.05).  Inclusion of ethanol significantly (p<0.05) reduced film 370 
thickness to about 165 µm, due to the formulations’ lower methacrylate content. FT-IR of 371 
the films showed no drug-polymer interactions.   372 
 373 
3.4.2 Drug loading and stability:  Drug in the film was in the dissolved state, and its 374 
concentration in the film was similar to that in the gel shown in Table 3 (p>0.05).  Upon 375 
storage of the films for 28 days under accelerated stability conditions, the drug levels 376 
remained the same, and the drug remained dissolved for at least two weeks, with a few 377 
drug crystals appearing in week 3. There were no differences among films with/without 378 
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ethanol, with/without drug and containing the different methacrylate-based monomers 379 
(Supplementary data 4).   380 
 381 
3.4.3  Glass transition temperatures of films.  The films produced from ethanol-free 382 
formulations showed two transition temperatures (Table 4).  It is thought that the lower Tg 383 
value is the polymer’s Tg caused by UV curing of the gel mixture, and that the second Tg is 384 
related to a thermal cure which occurred during the DMA measurement.  The UV-cure 385 
related Tg is influenced by the nature of the methacrylate-based monomer, with EMA- 386 
based gel having higher Tg than HEMA-based one, which in turn had higher Tg than IBOMA-387 
based one (p<0.05).  Such a difference in gel Tgs could be due to their different viscosities, 388 
which were 367 mPas, 598 mPas and 672mPas for EMA- , HEMA- and IBOMA- based gels 389 
respectively.  The negative correlation between gel viscosity and polymer Tg can be 390 
explained by the fact that, in a reaction mixture with lower viscosity, reactants are likely to 391 
be more mobile, which would increase the likelihood of polymerisation and of cross-linking 392 
and which would in turn increase the resulting polymer’s Tg.  393 
Inclusion of ethanol in the formulation had a major influence on the films’ glass transition 394 
temperatures, resulting in films with only one Tg, and increasing the UV-cure Tg (p<0.05).  395 
The higher Tgs reflect the greater extent of polymerisation (shown by higher degrees of 396 
conversion and lower levels of residual monomers in Supplementary Data 3b) in ethanol-397 
containing formulations and could also be a result of these gels’ much lower viscosities.   398 
  399 
3.4.4  In vitro adhesion and water sensitivity of films: In contrast to the in vivo situation 400 
where the presence of ethanol reduced the in vivo residence of the films (Figure 1), the 401 
three in vitro tests used (Instron pull-off, the cross-cut and water sensitivity) showed no 402 
influence of ethanol, or of the nature and concentration of the methacrylate monomer on 403 
film adhesion and water sensitivity (p>0.05,  Supplementary data 5). It seems that DUDMA 404 
(present at a much higher content than the methacrylate monomer in the film) is the main 405 
factor responsible for the adhesion and water-resistance properties of the films in vitro.  406 
 407 
16 
 
3.4.5  In vitro drug release:  Drug release profiles (Figures 4-5) of all the UV-cured films 408 
(containing the maximum amount of drug that could be loaded in the dissolved state in each 409 
film) showed a burst release over the first 24 hours, followed by a slower phase, followed by 410 
a plateau.  Examination of the films at the end of the release study showed negligible 411 
change in film mass over the study duration and no drug precipitation.  Fitting of the release 412 
data using zero order, first order and Higuchi models showed the best fit to be the Higuchi 413 
model (r2 ≥ 0.8), indicating drug release to be diffusion-controlled through the film matrix 414 
following the burst release phase.    415 
 416 
For both drugs, release was incomplete over the 30-day experiment as shown when % drug 417 
release was plotted against time (Supplementary data 6).  The amorolfine-containing films 418 
released about 46% of their drug load, while the terbinafine-containing films released about 419 
26% of their drug load during the 30-day study.  The reason(s) for the greater amorolfine 420 
release is as yet unclear.  The respective amorolfine- and terbinafine- loaded gels have 421 
similar reactants-to-film mass conversion, alkene-to-alkane degree of conversion, film 422 
thickness, glass transition temperatures, water sensitivity and dense internal structure.  It is 423 
possible that terbinafine binds to a greater extent to the polymer film compared to 424 
amorolfine, which would hinder its release.  425 
 426 
In addition to the nature of the drug, the nature of the methacrylate-based monomer also 427 
has an impact on the extent of drug release, via its influence on drug solvency, and 428 
consequently, on drug loading in the film.  Films produced using EMA and IBOMA (both non-429 
solvents for the drugs) contained the same drug loadings (3% amorolfine or 4% terbinafine), 430 
which was solely due to the presence of the ethanol.  In contrast, films produced using 431 
HEMA (a solvent for the drugs) could have a certain drug loading in the absence of ethanol 432 
(2% of amorolfine or of terbinafine), and the drug loading was considerably increased in the 433 
presence of ethanol (to 4% amorolfine or 6% terbinafine).  As the release studies were 434 
conducted using films containing the maximum drug loading, the drug concentrations in the 435 
films varied from 2% to 4% for amorolfine, and from 2% to 6% for terbinafine.  For both 436 
drugs, the greatest drug release at the end of the experiment was obtained from the films 437 
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containing the highest drug concentration, i.e. the film containing HEMA and ethanol 438 
(p<0.05, Figures 4-5).  Drug concentration in the film is thus an important parameter 439 
governing the extent of drug release. Both the nature of the methacrylate-based monomer 440 
and the inclusion of ethanol influenced drug release, via their influence on drug 441 
concentration in the film.  442 
 443 
When drug release from the control Curanail lacquer film was examined , it was found that 444 
like the UV-cured films, the Curanail lacquer film containing amorolfine also showed a burst 445 
of drug release (Supplementary data 6a).  In contrast to the UV-cured films however, the 446 
Curanail polymer film released most of its drug load, possibly due to the fact that the film 447 
disintegrated during the 30-day study.   448 
 449 
3.4.6  In vitro ungual drug permeation: The ungual drug permeation profiles and the 450 
permeation parameters are shown in Figures 6-7 and Table 5. Mass balance calculations are 451 
shown in Supplementary Data 7.   The fairly lengthy lag times in Table 5 are typical of ungual 452 
permeation (McAuley et al., 2016) and are due to the poor permeability of the nailplate. The 453 
latter is also evidenced by the very small percentage (maximum of 6%) of applied drug  454 
which permeated into and through the nail (Supplementary Data 7).   455 
 456 
Examination of the ungual permeation profiles shows significant influence of the drug 457 
nature and concentration, with amorolfine and the higher drug loadings resulting in greater 458 
ungual permeation (p<0.05).  Thus, amorolfine-containing formulations showed significantly 459 
higher steady-state flux and permeability coefficient (p<0.05) compared to the respective 460 
terbinafine-containing ones.  This reflects the greater amorolfine released (discussed in 461 
section 3.4.5), and thereby its greater availability for ungual permeation.  An additional 462 
cause for the higher amorolfine permeation could be its lower affinity to nail keratin, 463 
compared to that of terbinafine (Tatsumi et al., 2002).  Drug-keratin affinity could also 464 
explain the similar drug-in-nail concentrations at the end of the permeation experiments 465 
(p>0.05; Table 5) despite the lower terbinafine release from the films. 466 
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 467 
For both drugs, drug loading in the film was the maximum possible (while keeping the drug 468 
dissolved) and was related to the nature of the methacrylate-based monomer, and the 469 
presence of ethanol as discussed in section 3.4.5.  From Figures 6-7, it can be seen that as 470 
drug concentration in the film increased, drug permeation increased.  This reflects the 471 
greater amounts of drug released at the highest drug loadings (section 3.4.5) and 472 
consequently, greater drug availability for ungual permeation. Thus, the choice of the 473 
monomer and addition of ethanol had important consequences on ungual drug permeation, 474 
with the addition of ethanol to HEMA-based formulations significantly increasing drug 475 
loading and flux (p<0.05). 476 
 477 
The ungual permeation of amorolfine from the control Curanail was similar to that from the 478 
‘best’ UV-cured film (p>0.05 for the permeation curve, permeability coefficients, diffusion 479 
coefficients and drug-in-nail at day 30).  Curanail® nail lacquer however showed a slightly 480 
greater steady-state flux (p<0.05) probably due to its higher drug-load (32% w/w in the film 481 
vs. 4% w/w) and much greater drug release (shown in Supplementary Data 6a). However, 482 
the UV-cured film displayed a shorter lag time possibly due to its greater occlusivity 483 
compared to the lacquer film (Fig. 9), which could increase nail hydration, which is known to 484 
enhance permeation (Gunt and Kasting, 2007; Gunt et al., 2007).  485 
 486 
3.4.7  In vitro anti-fungal efficacy: The in vitro anti-fungal efficacy of the formulations was 487 
measured using an anti-fungal whole cell phenotypic assay, that we adapted from the 488 
classical disc diffusion method, in our laboratories. In the negative controls (i.e. where a 489 
drug-free formulation was cured onto a nail clipping), the T. rubrum culture grew over the 490 
entire plate’s surface (Table 6). In contrast, no T. rubrum growth was observed when drug-491 
loaded formulations had been cured on the nail clippings.  This shows that sufficient anti-492 
fungal drug was released from the UV-cured film, permeated into the nailplate, and 493 
subsequently permeated out of the nail plate and into the agar gel to inhibit fungal growth.  494 
The UV-cured gels are thus promising topical carriers for anti-onychomycotic drugs.  495 
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All the gels tested showed complete inhibition of fungal growth (example shown in Table 6), 496 
and no difference could be discerned among the formulations (in Supplementary data 7).  497 
This could be related to the fact that the amounts of drug present in the nail and that had 498 
permeated through the nail plate were fairly similar for all the formulations (as shown in 499 
Figures 6-7).  In these anti-fungal assays, the ethanol-free gels with the lowest drug load was 500 
as good as the ethanol-containing gels with the highest drug load.  It seems that the 501 
increased drug loading afforded by the inclusion of ethanol in the gels, which results in 502 
increased flux was not necessary for anti-fungal kill in this in vitro set-up.  Optimisation of 503 
the in vitro anti-fungal methodology is needed and it might enable discrimination among 504 
the formulations or confirm anti-fungal equivalence despite different drug loadings, release 505 
and ungual permeation. 506 
 507 
3.4.8  In vivo occlusivity of the UV-cured films: The UV-cured films reduced trans-onycheal 508 
water loss (TOWL) by about 40% (Figure 8), and were more occlusive than the control 509 
Curanail lacquer film.  Occlusion is desirable, as a reduction in TOWL has been hypothesised 510 
to hyper-hydrate the nail plate (Marty, 1995; Spruit, 1971), which is in turn beneficial for 511 
ungual drug permeation (Gunt and Kasting, 2007; Gunt et al., 2007).  A second benefit of 512 
increased nail plate hydration in the treatment of onychomycosis is that hydration could 513 
induce the germination of drug-resistant fungal spores into drug-susceptible hyphae, which 514 
would enable fungi eradication (Flagothier et al., 2005).  From Figure 8, it can be seen that 515 
ethanol or drug or the nature of the methacrylate monomer in the UV-cured films did not 516 
have any influence on the films’ occlusivity (p>0.05).  This indicates that DUDMA (present in 517 
the film at a much higher content than the methacrylate monomer) is  the main factor 518 
responsible for the occlusivity of the films. 519 
 520 
4. Conclusions 521 
Drug-loaded diurethane dimethacrylate-based UV gels, with or without ethanol, and 522 
containing one of  three different monomers (EMA, IBOMA or HEMA) were produced and 523 
characterised to determine the influence of the monomers, ethanol and drugs on the gel 524 
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and resulting films’ properties, and to explore correlations among the films’ characteristics.  525 
The drugs – amorolfine HCl and terbinafine HCl – had negligible influence on the films’ 526 
properties, except for the extent of their release and ungual flux, with amorolfine release 527 
from the film and ungual flux being much higher compared to that of terbinafine. The major 528 
influence of ethanol was its ability to increase drug loading, reduce gel viscosity, increase 529 
polymerisation and alter the films’ Tg.  The greater drug loading enabled by ethanol resulted 530 
in higher drug release and ungual flux.  However, ethanol inclusion had a negative impact on 531 
the film’s in vivo residence, which shows the importance of screening the other 532 
methacrylate monomers in order to identify suitable ones.   The major difference among the 533 
monomers was the fact that HEMA dissolves the drugs to some extent and enabled 534 
sufficient drug loading, such that ethanol-free formulations could be developed.  All the 535 
formulations inhibited anti-fungal growth to the same extent i.e. fully, and differences 536 
among the formulations regarding anti-fungal efficacy could not be discerned in the tests 537 
used i.e  there was no influence of methacrylate monomer nature, ethanol inclusion and 538 
drug concentration on anti-fungal activity.  The UV gels’ anti-fungal activities and long in 539 
vivo residence further show the promise of these formulations as nail medicines. 540 
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Figure legends 607 
Figure 1 In vivo residence of UV-cured films (± ethanol and ± drug) on the ten fingernails in 608 
six volunteers.  Curanail lacquer (containing amorolfine HCl) was used as a commercially 609 
available control.  Abbreviations: ETOH – ethanol; AH – amorolfine HCl; TH – terbinafine HCl. 610 
Means and standard deviations are shown, n=60. 611 
Figure 2: Chemical structures and viscosities of the different methacrylate-based monomers 612 
Figure 3: Scanning electron micrographs of the top surface (i.e. exposed to UV light), under 613 
surface (i.e. in contact with the support), and cross-sectional surface of a drug-free, ethanol-614 
free UV-cured film (DUDMA:HEMA 85:15).  Films with the other methacrylate monomers, 615 
and ± ethanol and ± drug (amorolfine HCl or terbinafine HCl) had similar micrographs. 616 
Figure 4: Cumulative amount of drug release from the amorolfine HCl loaded UV-cured films. 617 
Means and standard deviations are shown, n=3. Abbreviations: AH, amorolfine HCl; ETOH, 618 
ethanol. 619 
Figure 5: Cumulative amount of drug release from the terbinafine HCl loaded UV-cured. 620 
Means and standard deviations are shown, n=3. Abbreviations: TH, terbinafine HCl; ETOH, 621 
ethanol.622 
Figure 6: Cumulative amount of amorolfine HCl permeated across the nail with time from 
the UV-cured and Curanail® films, and the % of drug permeated across the nail and 
remaining in the nail at day 30. Means and standard deviations are shown, n=6. 
Abbreviations: AH, amorolfine HCl; ETOH, ethanol. 
Figure 7: Cumulative amount of terbinafine HCl permeated across the nail with time from 
the UV-cured films, and the % of drug permeated across the nail and remaining in the nail at 
day 30. Means and standard deviations are shown, n=6. Abbreviations: TH, terbinafine HCl; 
ETOH, ethanol. 
Figure 8: Reduction of TOWL by the different UV-cured films and the Curanail lacquer film 
control. Means and standard deviations are shown.  n=5 
 
 
 Table 1:  Table shows details of test formulations used for anti-fungal efficacy assessment.  In addition, drug-free counterparts of these and 
Curanail were used as controls. 
Nature of monomer Ethanol concentration Drug nature and 
concentration 
EMA 25% Amorolfine HCl; 3% 
IBOMA 25% Amorolfine HCl; 3% 
HEMA 25% Amorolfine HCl; 4% 
HEMA None Amorolfine HCl; 2% 
HEMA 25% Terbinafine HCl; 6% 
 
 
  
Table(s)
Table 2 Solubilities of amorolfine HCl and terbinafine HCl in the three methacrylate monomers; means and standard deviations are shown, 
n=3. 
 Solubility (mg/ml) 
EMA IBOMA HEMA 
Amorolfine HCl 0.10 ± 0.01  0.19 ± 0.02 209.3 ± 9.4 
Terbinafine HCl 0.66 ± 0.19 0.12 ± 0.02 229.0 ± 9.8 
 
  
  
Table 3 Theoretical and actual drug-load in UV-curable gel formulations. AH- amorolfine HCl, TH- terbinafine hydrochloride. N=3. Sd=0 for all. 
The theoretical (based on drug solubility in the gel components) and actual (determined by the absence/presence of drug crystals in the 
formulation) drug loadings were fairly similar for all the gels except for ethanol-free HEMA-containing gels, where the actual drug-load was 
much lower than anticipated, due to drug precipitation upon mixing with DUDMA and the photoinitiator. 
 
Solvent Methacrylate-based 
monomer 
Drug Expected Drug load (% w/v) Actual drug load (% w/v) 
Ethanol (25% v/v) EMA AH 3.0 3 
TH 3.5 4 
IBOMA AH 3.0 3 
TH 3.5 4 
HEMA AH 5.2 4 
TH 6.0 6 
None HEMA AH 5.1 2 
TH 5.6 2 
 
 
  
 Table 4: Transition temperatures (Tg) of UV-cured films. Means ± standard deviations are shown, n=3.  
 
 
Tg values of UV-cured films produced from formulations containing 
Excipients DUDMA Solvent 
Ethanol 
Drug EMA IBOMA HEMA 
     
 
 
 
 
 
Formulations 
 
 
 
DUDMA 85 % v/v : 
diluent monomer 15 % v/v 
None None 85.7 ± 1.2 and 
146.0 ± 2.5 
67.2 ± 2.4 and 
164.0 ± 0.2 
74.4 ± 2.5 and 
147.2 ± 0.3 
 
25% v/v 
None 112.5 ± 1.8 139.2 ± 9.0 98.1 ± 2.3 
AH 109.2 ± 1.1 137.2 ± 0.02 99.2 ± 1.8 
TH 109.6 ± 0.8 133.4 ± 3.6 94.7 ± 4.8 
 
None 
None 95.1 ± 1.5 NF NF 
AH 94.8 ± 2.0 NF NF 
TH 95.0 ± 1.8 NF NF 
 
 
DUDMA 75 % v/v : 
diluent monomer 25 v/v 
 
 
None 
None NF NF 81.8 ± 0.5 and 
142.6 ± 0.4 
AH NF NF 92.0 ± 0.9 and 
138.9 ± 0.5 
TH NF NF 92.4 ± 0.4 and 
133.2 ± 0.2 
Tg of homopolymers 
(⁰C) 
- - - 65 110 57 
 
  
Table 5  Ungual permeation parameters. Lag time, steady-state flux, permeability coefficient, diffusion coefficient and amount of drug in nail 
clippings. Means and standard deviations are shown, n=6. Abbreviations: AH, amorolfine HCl; TH, terbinafine HCl; ETOH, ethanol. 
 
 
 
 
  
 
 
Amorolfine HCl (AH) Terbinafine HCl (TH) 
% in 
formula-
tion  
(% w/v) 
 
Lag time 
(day) 
Steady-state 
flux 
(µg/cm2/day) 
Permeability 
coefficient  
x 10-5 
(cm/day) 
Diffusion  
coefficient  
x 10-5  
(cm2/day) 
Drug in 
nail 
clipping 
(mg/cm3) 
% in 
formula-
tion 
(% w/v) 
 
Lag time 
(day) 
Steady-state 
flux 
(µg/cm2/day) 
Permeability 
coefficient  
x 10-5 
(cm/day) 
Diffusion 
coefficient 
x 10-5 
(cm2/day) 
Drug in 
nail 
clipping 
(mg/cm3) 
Curanail® nail lacquer 5 10.4 ± 1.3 2.9 ± 0.2 5.8 ± 0.3 2.5 ± 0.5 0.6 ± 0.2 NA NA NA NA NA NA 
DUDMA & EMA 
gel containing 
ETOH & AH or TH 
3 10.4 ± 0.9 2.4 ± 0.2 7.9 ± 0.7 2.7 ± 0.8 0.3 ± 0.2 4 9.5 ± 1.2 1.5 ± 0.1 3.7 ± 0.3 1.6 ± 0.4 0.9 ± 0.2 
DUDMA & IBOMA 
gel containing 
ETOH & AH or TH 
3 10.5 ± 0.6 2.3 ± 0.3 7.8 ± 1.0 2.2 ± 0.4 0.4 ± 0.1 4 8.3 ± 0.8 1.4 ± 0.3 3.4 ± 0.8 3.1 ± 0.9 0.4 ± 0.1 
DUDMA & HEMA 
gel containing 
ETOH & AH or TH 
4 7.1 ± 1.7 2.2 ± 0.3 5.5 ± 0.7 3.5 ± 1.4 0.6 ± 0.1 6 7.1 ± 1.0 1.6 ± 0.2 2.6 ± 0.4 3.0 ± 0.8 0.7 ± 0.2 
DUDMA & HEMA 
gel containing 
AH or TH 
2 10.0 ± 1.9 1.4 ± 0.1 7.0 ± 0.7 3.2 ± 0.4 0.3 ± 0.2 2 8.9 ± 1.0 0.7 ± 0.1 3.5 ± 0.7 2.6 ± 0.9 0.3 ± 0.1 
  
Table 6  Photographic images (at day 30) of T. rubrum inoculated SDA plates containing nail clippings with drug-free and drug-loaded formulations cured on the surface. An 
example, using the ethanol-free HEMA containing formulation is shown.  All the other formulations showed similar anti-fungal activity and the images are shown in the 
Supplementary file. 
Formulation 
applied on  
nail clipping 
surface 
T. rubrum inoculated SDA plates containing nail 
clippings with drug-loaded  formulations cured 
on the surface (n=3) and the corresponding 
drug-free formulation cured on the surface (C) 
T. rubrum inoculated SDA plates containing nail 
clippings with drug-free formulations cured on 
the surface (n=3) 
Top surface Under surface Top surface Under surface 
 
 
None  
(nail clipping-
free  & 
formulation-free 
control) 
    
 
 
 
DUDMA & 
HEMA  
gel  
± 2% w/v AH 
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Figure 1 In vivo residence of UV-cured films (± ethanol and ± drug) on the ten fingernails in six volunteers; n=60, means and standard 
deviations are shown.  Curanail lacquer (containing amorolfine HCl) was used as a commercially available control.  Abbreviations: ETOH – 
ethanol; AH – amorolfine HCl; TH – terbinafine HCl.   
Figure(s)
 Ethyl methacrylate, MW 114, Viscosity 0.62 mPas 
 
 Isobornyl methacrylate, MW 222, Viscosity 7.40 mPas 
 
 Hydroxyethyl methacrylate, MW 130, Viscosity 6.79 mPas 
 
 
Figure 2: Chemical structures and viscosities of the different methacrylate-based monomers 
  
       Top surface         Under surface           Cross-section 
Figure 3: Scanning electron micrographs of the top surface (i.e. exposed to UV light), under surface (i.e. in contact with the support), and cross-
sectional surface of a drug-free, ethanol-free UV-cured film (DUDMA:HEMA 85:15).  Films with the other methacrylate monomers, and ± 
ethanol and ± drug (amorolfine HCl or terbinafine HCl) had similar micrographs. 
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Figure 4: Cumulative amount of drug released from the amorolfine HCl loaded UV-cured films.  Means and standard deviations are shown, n=3. 
Abbreviations: AH, amorolfine HCl.   
 
 
 
 
0 5 10 15 20 25 30
0
20
40
60
80
100
120
140
160
 DUDMA & HEMA gel containing ETOH & 6% w/v TH
 DUDMA & IBOMA gel containing ETOH & 4% w/v TH
 DUDMA & HEMA gel containing 2% w/v TH
 DUDMA & EMA gel containing ETOH & 4% w/v TH
C
u
m
u
la
ti
v
e
 a
m
o
u
n
t 
o
f 
te
rb
in
a
fi
n
e
 H
C
l 
(T
H
) 
re
le
a
s
e
d
 (

g
/c
m
3
)
Time (days)  
 
Figure 5: Cumulative amount of drug released from the terbinafine HCl loaded UV-cured films. Means and standard deviations are shown, n=3. 
Abbreviations: TH, terbinafine HCl. 
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Figure 6 Cumulative amount of amorolfine HCl permeated across the nail with time from the UV-cured and Curanail® films, and the % of 
amorolfine HCl permeated across the nail and remaining in the nail at day 30. Means and standard deviations are shown, n=6. Abbreviations: 
AH, amorolfine HCl; ETOH, ethanol. 
The permeation profiles for the gel containing the highest drug load (4% amorolfine HCl) was significantly different (p<0.05) to those 
containing 3% w/v amorolfine HCl which were similar (p>0.05), and which were in turn significantly higher (p<0.05) than the gel containing the 
lowest drug load (2% w/v amorolfine HCl).  The steady-state flux was lowest (p<0.05) from the film with the lowest drug load.  
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Figure 7 Cumulative amount of terbinafine HCl permeated across the nail with time from the UV-cured films, and the % of terbinafine HCl 
permeated across the nail and remaining in the nail at day 30. Means and standard deviations are shown, n=6. Abbreviations: TH, terbinafine 
HCl; ETOH, ethanol.   
The permeation profiles for the gel containing the highest drug load (6% terbinafine HCl) was significantly different (p<0.05) to those 
containing 3% w/v terbinafine HCl, which were similar (p>0.05), and which were in turn significantly higher (p<0.05) than the gel containing the 
lowest drug load (2% w/v terbinafine HCl).  The steady-state flux was lowest (p<0.05) from the film with the lowest drug load.  
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Figure 8: Reduction of TOWL by the different UV-cured films and the Curanail lacquer film control. Means and standard deviations are shown.  
n=5 
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